IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Caxton Corp

Q2 2025 Holdings

Filed 2025-08-14 | 11 holdings | $9.9M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Rezolute Inc(RZLT)COM NEW76200L309$7.2M1,603,98672.6%
Spdr Gold TR(GLD)GOLD SHS78463V107$1.5M4,95215.3%
Berkshire Hathaway Inc del(BRK/B)CL B NEW084670702$307.0K6323.1%
Enliven Therapeutics Inc(ELVN)COM29337E102$262.7K13,0972.7%
Mind Medicine Mindmed Inc(BRD1EUR)COM NEW60255C885$221.1K34,0732.2%
Compass Therapeutics Inc(CMPX)COM20454B104$113.0K43,4651.1%
Bicara Therapeutics Inc(BCAX)COM055477103$101.6K10,9411.0%
Kyverna Therapeutics Inc(KYTX)COM501976104$70.6K22,9810.7%
Lexeo Therapeutics Inc(LXEO)COM52886X107$69.7K17,3320.7%
Inhibikase Therapeutics Inc(IKT)COM NEW45719W205$32.0K16,3930.3%
Context Therapeutics Inc(CNTX)COM21077P108$12.1K18,4030.1%